Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Michele Del Vecchio

doi:10.1701/2332.25062

Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab

Michele Del Vecchio

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

Translated title of the contribution	AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab
Original language	Italian
Pages (from-to)	414-7
Number of pages	4
Journal	Recenti Progressi in Medicina
Volume	107
Issue number	8
DOIs	https://doi.org/10.1701/2332.25062
Publication status	Published - Aug 2016

Keywords

English Abstract
Journal Article

Access to Document

10.1701/2332.25062

Cite this

@article{99abfe6a952941a5b77db913b33e5fbd,

title = "Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab",

abstract = "The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.",

keywords = "English Abstract, Journal Article",

author = "{Del Vecchio}, Michele",

year = "2016",

month = aug,

doi = "10.1701/2332.25062",

language = "Italian",

volume = "107",

pages = "414--7",

journal = "Recenti Progressi in Medicina",

issn = "0034-1193",

publisher = "Il Pensiero Scientifico Editore s.r.l.",

number = "8",

}

TY - JOUR

T1 - Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

AU - Del Vecchio, Michele

PY - 2016/8

Y1 - 2016/8

N2 - The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

AB - The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.

KW - English Abstract

KW - Journal Article

U2 - 10.1701/2332.25062

DO - 10.1701/2332.25062

M3 - Articolo

C2 - 27571556

SN - 0034-1193

VL - 107

SP - 414

EP - 417

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

IS - 8

ER -

Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Abstract

Keywords

Access to Document

Fingerprint

Cite this